 | This article needs additional citations for verification. (February 2017) |
| Abbreviation | TB Alliance |
|---|---|
| Established | February 2000 |
| Type | Nonprofit |
| Legal status | Active |
| Headquarters | New York City, Pretoria |
Chief Executive Officer | Mel Spigelman |
| Website | www |
TB Alliance (formally The Global Alliance for TB Drug Development) is a not-for-profit product development partnership (PDP) dedicated to the discovery and development of new, faster-acting and affordable tuberculosis (TB) medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history.[1] It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria.[2]
- ^ "Clinical Portfolio | TB Alliance". www.tballiance.org. Retrieved 2019-04-25.
- ^ "Home". TB Alliance 2016 Annual Report. Retrieved 2019-04-25.